Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

12 Days of Regulatory Insights: Day 3 – State AG Oversight in the Health Care Industry

By Chris Carlson & Barry Boise on December 9, 2024
Email this postTweet this postLike this postShare this post on LinkedIn

In the third episode of our special 12 Days of Regulatory Insights podcast series, Chris Carlson is joined by Barry Boise, a seasoned partner in Troutman Pepper’s Health Sciences Litigation practice group, to explore the increasing oversight of the health care industry by state attorneys generals (AGs) in 2024 and what to anticipate in 2025.

Barry begins by explaining the broad statutory authority of state AGs under the Unfair and Deceptive Trade Practices Acts and state equivalents to the False Claims Act. He highlights the historical application of these statutes in heavily regulated industries like health care.

Shifting to the opioid crisis, which has been a significant focus for state AGs, Barry explains how municipalities have stepped in to fill perceived gaps left by federal enforcement and how broader enforcement tools have been used in opioid litigation. The episode also covers state AGs’ actions in addressing drug pricing issues, including the use of antitrust tools and transparency laws.

Looking ahead to 2025, Barry and Chris discuss the potential impact of the upcoming presidential administration on state AG enforcement activities.


Transcript: 12 Days of Regulatory Insights: Day 3 – State AG Oversight in the Health Care Industry (PDF)

Photo of Chris Carlson Chris Carlson

Chris Carlson represents clients in regulatory, civil and criminal investigations and litigation. In his practice, Chris regularly employs his prior regulatory experience to benefit clients who are interacting with and being investigated by state attorneys general.

Read more about Chris CarlsonEmailChris's Linkedin Profile
Photo of Barry Boise Barry Boise

Barry’s primary emphasis is the counseling and defense of pharmaceutical and medical device companies from early stage through marketed products. He has substantial experience litigating multidistrict litigation and coordinated state court litigation. Barry represents life science, health care, and technology companies in attorney…

Barry’s primary emphasis is the counseling and defense of pharmaceutical and medical device companies from early stage through marketed products. He has substantial experience litigating multidistrict litigation and coordinated state court litigation. Barry represents life science, health care, and technology companies in attorney general investigations and litigation, and in other civil and criminal actions involving health care fraud and abuse.

Read more about Barry BoiseEmail
Show more Show less
  • Posted in:
    Administrative and Regulatory, Antitrust, Competition and Trade, Health Care and Life Sciences
  • Blog:
    Regulatory Oversight
  • Organization:
    Troutman Pepper Locke
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo